Related Experiment Video

Updated: May 25, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Risk factors for severe respiratory syncytial virus lower respiratory tract infection

Constanze Sommer1, Bernhard Resch, Eric A F Simões

  • 1Medical University Graz, Austria.

The Open Microbiology Journal
|January 21, 2012
PubMed

Insights

Respiratory Syncytial Virus (RSV) infection poses a significant risk to infants, particularly those with underlying health conditions. Identifying high-risk infants is crucial for effective RSV prevention strategies and treatment with palivizumab.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Public Health

Background:

  • Respiratory Syncytial Virus (RSV) is a primary cause of lower respiratory tract infections in infants.
  • Certain infants, including those with prematurity, bronchopulmonary dysplasia (BPD), and congenital heart disease (CHD), face higher risks.
  • Numerous host-related and environmental factors contribute to severe RSV infection and acquisition risk.

Purpose of the Study:

  • To identify and discuss host-related risk factors for severe RSV lower respiratory tract infection.
  • To explore factors influencing the acquisition of RSV in infants.
  • To evaluate the utility of risk score systems in identifying infants eligible for palivizumab prophylaxis.

Main Methods:

  • Literature review of identified risk factors for severe RSV infection and acquisition.
  • Analysis of published risk score systems and algorithms for palivizumab prophylaxis eligibility.
  • Assessment of the sensitivity and specificity of existing risk models.

Main Results:

  • Younger age, male sex, low socioeconomic status, crowded living, and maternal smoking are associated with severe RSV.
  • Birth during RSV season, daycare attendance, and lack of breastfeeding increase RSV acquisition risk.
  • Risk score systems demonstrate an average sensitivity and specificity of 70% in identifying high-risk infants.

Conclusions:

  • Effective identification of high-risk infants is essential for targeted RSV prevention.
  • Risk score systems offer valuable support in clinical decision-making for palivizumab prophylaxis.
  • Further refinement of risk assessment tools may improve the management of RSV in vulnerable infant populations.

Keywords:
IgA antibodiesRSV diseaseSyncytial viruscellular immunity.immune complex reaction

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Concept Videos

Common Respiratory Disorders01:31

Common Respiratory Disorders

Respiratory disorders, a prevalent health concern globally, are generally divided into two primary categories: upper and lower respiratory tract disorders. The categorization is based on the area of the respiratory system they affect.
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pulmonary Cycle: Exhalation01:17

Pulmonary Cycle: Exhalation

In terms of human respiration, the act of expelling air, known as exhalation (or expiration), operates on the principle of pressure gradients. During expiration, the pressure within the lungs exceeds that of the surrounding atmosphere. Under normal conditions, quiet breathing involves passive exhalation and is free of muscular contractions. This is because the exhalation process is driven by the natural elastic recoil of the lungs and chest wall, both of which have an inherent tendency to...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...